Wanbury Ltd

Wanbury Ltd

$WANBURYPharmaceuticalsNSEBSE

Wanbury Ltd (WANBURY) last traded at ₹264, a market capitalisation of ₹923 crore, on a P/E of 21.5. Over the past 52 weeks the stock has ranged between ₹162 and ₹360. Wanbury Ltd last reported results for the quarter ended Jun 2025, with sales of ₹163 crore and net profit of ₹13 crore. Figures are as of 25 Aug 2026 and are not real time.

Wanbury Ltd share price and key metrics

Current price
₹264
Market cap
₹923 cr
Stock P/E
21.5
Book value
₹18.1
ROE
76.5%
ROCE
36.6%
Dividend yield
0.00%
52w high / low
360/162

Metrics as of 25 Aug 2026. Not real time.

Wanbury Ltd quarterly results

In the quarter ended Jun 2025, sales were ₹163 cr, up 24.4% from ₹131 cr a year earlier. Net profit was ₹13 cr, up 1200.0% year on year.

Wanbury Ltd consolidated quarterly results, figures in ₹ crore
₹ croreSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025
Sales144146139131161133172163
Expenses127124121120141120142139
Operating profit1721181120143024
OPM %12%15%13%8%12%10%17%15%
Other income112612120
Interest8878101098
Depreciation33333334
Profit before tax710341811914
Tax %-2%-0%1%0%2%5%-6%1%
Net profit710341812013
EPS (₹)2.253.1410.270.322.450.376.184.10

Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.

Wanbury Ltd annual results

Wanbury Ltd annual profit and loss, figures in ₹ crore
₹ croreMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales367392511485557600630
Operating profit23183626738088
OPM %6%4.7%7%5%13%13%14%
Net profit64-1381-10563143
EPS (₹)25.79-5.0424.94-3.1817.099.3213.10

TTM is the trailing twelve months to the most recent quarter.

Wanbury Ltd growth and returns

Compounded Sales Growth
10 Years
9%
5 Years
10%
3 Years
5%
TTM
12%
Compounded Profit Growth
10 Years
26%
5 Years
31%
3 Years
80%
TTM
60%
Stock Price CAGR
10 Years
20%
5 Years
26%
3 Years
73%
1 Year
-8%
Return on Equity
10 Years
%
5 Years
%
3 Years
%
Last Year
77%

Wanbury Ltd shareholding pattern

Promoters held 43.01% at Jun 2026, up from 39.63% at Jun 2025. FIIs 0.89% and DIIs 0.06%.

Wanbury Ltd shareholding pattern by quarter, in percent
% heldSep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters39.77%39.76%39.76%39.63%43.09%43.08%43.01%43.01%
FIIs1.02%0.84%1.55%1.59%0.82%0.72%0.59%0.89%
DIIs0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.06%
Public59.21%59.40%58.68%58.79%56.08%56.21%56.39%56.04%
No. of shareholders17,19917,99917,88917,89417,71717,26116,73217,174

As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.

Wanbury Ltd corporate filings

  • Press Release regarding EDQM approval for new product Rivaroxaban API, USFDA DMF Clearances.Company Updatemedium impact
    Filing PDF

    Cruxal's analysis: Wanbury Ltd has secured European Directorate for the Quality of Medicines (EDQM) approval…

    Read the full analysis
  • Press Release on Un-audited Financial Results for the quarter ended 30th June, 2026Company Updatemedium impact
    Filing PDF

    Cruxal's analysis: Wanbury Limited reported Q1 FY27 revenue of 165.6 crore, a modest 1.5% YoY growth, while…

    Read the full analysis
  • Outcome of the Board Meeting held on August 11, 2026Board Meetinghigh impact
    Filing PDF

    Cruxal's analysis: Wanbury Limited reported Q1 FY27 revenue of 165.58 crore, showing a modest YoY increase…

    Read the full analysis

This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.

Track Wanbury Ltd

Cruxal reads every Wanbury Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.

Cruxal publishes market data and coverage for information only. Nothing here is investment advice.